Invetx Fetches $15M to Develop Biologic Drugs for Man’s Best Friend

Invetx is developing biologic medicines to treat diseases in pets and farm animals. As the Boston-based startup prepares to advance its first drug into clinical testing later this year, it has raised $15 million in Series A funding. The financing was led by Anterra Capital, Invetx’s founding investor. The round included money from WuXi Biologics, which will also collaborate with Invetx on its drug research.